Senate HELP Panel’s Confounded Markup Points To Challenges Ahead For Chairman Sanders

Session on PBM and generic legislation brought to a halt by Republican objections to amendments targeting FDA disclosure of inactive ingredient concentrations in brands, method-of-use patents, and using REMS to extend patent protection.